Drugs & Targets FDA approves Iwilfin for adult and pediatric patients with high-risk neuroblastoma December 15, 2023Vol.49 No.46
As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation December 08, 2023Vol.49 No.45By Matthew Bin Han Ong
Drugs & Targets FDA grants Fast Track designation to Alpha1H for non-muscle invasive bladder cancer December 08, 2023Vol.49 No.45
Clinical Roundup FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous CAR T-cell immunotherapies December 01, 2023Vol.49 No.44
Drugs & Targets FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence December 01, 2023Vol.49 No.44
Drugs & Targets FDA grants Breakthrough Therapy Designation to epcoritamab-bysp December 01, 2023Vol.49 No.44
White House As Biden invokes wartime powers to regulate AI, oncology braces for fundamental change November 17, 2023Vol.49 No.43By Matthew Bin Han Ong
Conversation with The Cancer Letter Paige’s Razik Yousfi: Biden has set expectations for AI, but details will come via federal guidelines November 17, 2023Vol.49 No.43By Matthew Bin Han Ong
Regulatory News ODAC reviews two longest-running accelerated approvals as FDA weighs using its new authority November 17, 2023Vol.49 No.43By Jacquelyn Cobb
